LakeShore Biopharma director files initial Form 3

LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders.

Accepted by SEC EDGAR 04/01/2026 - 09:59 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.

Key Figures

Reported transactions: 0 transactions

1 metrics

Reported transactions 0 transactions Initial Form 3 transactionSummary for Pan Yue

Key Terms

Form 3, reporting person, derivative securities

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [{"name": "Pan Yue""

derivative securities financial

""derivativeSummary": []"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does LakeShore Biopharma (LSB) director Pan Yue’s Form 3 filing mean?

Pan Yue’s Form 3 is an initial insider ownership report for LakeShore Biopharma. It formally registers Pan Yue as a director subject to insider reporting rules, but the provided data shows no reportable transactions or derivative positions at this time.

Does the LakeShore Biopharma (LSB) Form 3 for Pan Yue show any stock purchases or sales?

No, the Form 3 data provided shows no reportable stock purchases, sales, or other transactions by director Pan Yue. All transaction-related counts, including buys, sells, and exercises, are listed as zero in the transaction summary section.

Are there any derivatives reported for Pan Yue in the LakeShore Biopharma (LSB) Form 3?

The Form 3 data shows no derivative securities reported for Pan Yue. The derivative summary is empty and the transactionSummary lists zero derivative transactions and zero exerciseShares, indicating no options or similar instruments in this excerpt.

What insider role does Pan Yue hold at LakeShore Biopharma (LSB) according to the Form 3?

According to the Form 3 data, Pan Yue is reported as a director of LakeShore Biopharma and not as an officer or 10% beneficial owner. This status subjects Pan Yue to ongoing insider reporting requirements under Section 16 of U.S. securities rules.

Does the LakeShore Biopharma (LSB) Form 3 for Pan Yue indicate any gifts or tax-related share withholdings?

No, the transaction summary shows zero gifts and zero tax withholding entries for Pan Yue. Gift-related counts and taxWithholdingShares are all zero, indicating no such movements in the ownership information presented in this initial filing excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pan Yue

(Last) (First) (Middle)

C/O BUILDING NO. 2

38 YONGDA ROAD, DAXING DISTRICT

(Street)

BEIJING DAXING DISTRICT 102629

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
LakeShore Biopharma Co., Ltd. [ LSB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Yue Pan	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)